CMRX - Chimerix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919-806-1074
http://www.chimerix.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Dr. M. Michelle BerreyPres, CEO & Director724.37k9.58k1967
Mr. Timothy W. TrostSr. VP, CFO & Corp. Sec.460.78kN/A1958
Dr. William Garrett Nichols M.D., MSChief Medical Officer528.01kN/A1969
Dr. Roy W. Ware Ph.D., MBAChief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Randall Lanier Ph.D.Chief Science OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.’s ISS Governance QualityScore as of September 1, 2018 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.